BLU News and Press, BELLUS Health Inc. From 07/05/22

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indicati...

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indicati...

BELLUS Health press release (NASDAQ:BLU): Q1 GAAP EPS of -$0.13 beats by $0.06. Revenue of $4K (flat Y/Y). For further details see: BELLUS Health GAAP EPS of -$0.13 beats by $0.06, revenue of $4M

- End-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”) scheduled for June of 2022; Plan to initiate the Phase 3 program in the second half of 2022 - - Three late-breaking abstracts reviewing clinical data from the Phase 2b SOOTHE trial will b...

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indicati...

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indicati...

Gainers: Universal Display Corporation (OLED) +10%. United Airlines Holdings (UAL) +8%. Seres Therapeutics (MCRB) +7%. Tesla (TSLA) +7%. Sono Group  (SEV) +7%. Losers: Xilio Therapeutics (XLO) -14%. BELLUS Health  (BLU) -7%. Sleep Number Corporation (SNBR)&#...

BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indicati...

BELLUS Health press release (NASDAQ:BLU): FY GAAP EPS of -$0.90 beats by $0.01. Revenue of $16K. For further details see: BELLUS Health GAAP EPS of -$0.90 beats by $0.01, revenue of $16K

- Announced positive topline results from the Phase 2b SOOTHE clinical trial in refractory chronic cough (“RCC”), positioning BLU-5937 as a potentially best-in-class P2X3 antagonist - - Plans to request an End-of-Phase 2 meeting with the Food and Drug Administrat...